Furthermore, our ChIP assays revealed that EZH2 was able to directly bind onto the HOXB13 promoter (Fig. 4B), and this may be a silencing mechanism of HOXB13 in the DU145 malignant prostate cancer cells. Here, HOXB13 is linked to prostate carcinoma.